
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 07 December 2023
Sec. Cancer Molecular Targets and Therapeutics
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1334938
This article is a correction to:
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
by Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, Tan Y, Zhao X and Song H (2022) Front. Oncol. 12:951589. doi: 10.3389/fonc.2022.951589
Error in Table
In the published article, there was an error in Table 5 as published.
The corrected Table 5 and its caption “Payload KL610023 pharmacokinetic parameters in plasma after administrated in cynomolgus monkey (n=4, half male and half female)” appears below.
Table 5 Payload KL610023 pharmacokinetic parameters in plasma after administrated in cynomolgus monkey (n=4, half male and half female).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: antibody drug conjugate, SKB264, TROP2, PK-PD, solid tumor
Citation: Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, Tan Y, Zhao X and Song H (2023) Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol. 13:1334938. doi: 10.3389/fonc.2023.1334938
Received: 08 November 2023; Accepted: 15 November 2023;
Published: 07 December 2023.
Edited and Reviewed by:
Tristan M. Sissung, National Institutes of Health (NIH), United StatesCopyright © 2023 Cheng, Yuan, Tian, Huang, Chen, Pu, Long, Xu, Ji, Xie, Tan, Zhao and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongmei Song, c29uZ2hvbmdtZWlAa2VsdW4uY29t; Xi Zhao, emhhb3hpQGtlbHVuLmNvbQ==
†These authors have contributed equally to this work and share first authorship
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.